@possum2 the Tortoise definitely wanted to be the Here this week! Not surprised to see some supply come online after smashing through previous highs.
@valincarter, you can't look at the market cap in isolation. You have to take into account many elements. If Alcidion was listing as a concept or idea that is miles away from commercialisation (things we see very often) then a 40m cap would be a stretch.
But it's not. It's listing as a fully funded (and proven) MedTech business. It's currently breaking even on a very small penetration of the potential market and is gunning for the honey pot in the US.
@noodlesom very good post re: the share structure. Also important to note the resolution for Nathan Buzzer to take 6.4m shares in the CR. Like the guy needs more. Shows confidence.
Has looked at those contingent shares...
Each Class A Contingent share will be converted if Alcidion archives audited sales of at least $10,000,000 in a period of 12 consecutive months no later than two years from the re-listing. The Class B's are the same but for $15,000,000. The best type of motivation IMO.
NRR Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
